Egenesis Overview

  • Founded

  • 2015

Founded
  • Status

  • Private

  • Employees

  • 98

Employees
  • Latest Deal Type

  • Series C

  • Latest Deal Amount

  • $125M

  • Investors

  • 26

Egenesis General Information

Description

Developer of a gene editing and genome engineering platform intended to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases. The company's platform offers gene editing technics for the development of human-compatible organs, tissues and cells, enabling patients to recover and lead a healthy life.

Contact Information

Website
www.egenesisbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 300 Technology Square
  • Suite 301
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Egenesis Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Egenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 01-Mar-2021 $125M 00000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 01-Nov-2019 00000 00000 00000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 13-Mar-2017 $38M $38M 000.00 Completed Pre-Clinical Trials
To view Egenesis’s complete valuation and funding history, request access »

Egenesis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 21,934,976 $0.000020 $0.14 $1.8 $1.8 1x $1.8 12.23%
To view Egenesis’s complete cap table history, request access »

Egenesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a gene editing and genome engineering platform intended to transform solid organ and therapeutic cell trans
Biotechnology
Cambridge, MA
98 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

na aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000000000000
Cambridge, MA
000 As of 0000
0000
000000000 0000

000000

, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000000000000
Zug, Switzerland
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Egenesis Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Formerly PE-Backed Cambridge, MA 000 0000 000000000 0000
000000 00000000000 Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
0000000 00000000 Venture Capital-Backed Milpitas, CA 00 000.00 0000000000 000.00
0000000 0000000000 Formerly VC-backed Berkeley, CA 00 00000 00000000 00000
00000000 Private Debt Financed Mountain View, CA 00 000000000 -
You’re viewing 5 of 36 competitors. Get the full list »

Egenesis Executive Team (17)

Name Title Board Seat Contact Info
Michael Curtis Ph.D Chief Executive Officer & President
Albert Hwa Co-Chief Operating Officer
Peter Hanson Ph.D Co-Chief Operating Officer
Jennifer Bergheiser Chief Strategy Officer
Elizabeth Roberts Chief People Officer
You’re viewing 5 of 17 executive team members. Get the full list »

Egenesis Board Members (15)

Name Representing Role Since
Albert Wiegman II Fresenius Medical Care Ventures Board Member 000 0000
Bradford Smith Self Board Member 000 0000
Daniel Lynch Self Executive Chairman 000 0000
Isaac Ciechanover Ph.D Polaris Partners Board Member 000 0000
Julie Sunderland Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Egenesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Egenesis Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Altium Capital Investment Bank Minority 000 0000 000000 0
Catalio Capital Management Venture Capital Minority 000 0000 000000 0
E Squared Capital Management Hedge Fund Minority 000 0000 000000 0
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 26 investors. Get the full list »

Egenesis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 20-May-2020 0000000000 Drug Discovery 0000 0000
To view Egenesis’s complete acquisitions history, request access »

Ready to get started?

Request a free trial